Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug.
作者信息
Jain Nirmal Kumar
机构信息
Department of Respiratory Medicine, JNU Medical College, Jaipur, Rajasthan, India.
出版信息
Lung India. 2022 Jul-Aug;39(4):389-390. doi: 10.4103/lungindia.lungindia_31_22.
Abstract
摘要
相似文献
1
Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug.回复：在未进行药敏试验的情况下推广使用贝达喹啉会导致结核病高负担国家出现贝达喹啉耐药性——失去一种新药的风险。
Lung India. 2022 Jul-Aug;39(4):389-390. doi: 10.4103/lungindia.lungindia_31_22.
2
Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates.贝达喹啉耐药性在耐多药结核病（MDR-TB）中的出现评估：一项贝达喹啉和其他二线药物耐药性检测在 MDR-TB 分离株中的 5 年前瞻性监测研究。
J Clin Microbiol. 2022 Jan 19;60(1):e0291920. doi: 10.1128/JCM.02919-20. Epub 2021 Oct 27.
3
Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention.贝达喹啉耐药性：其出现、机制与预防。
Clin Infect Dis. 2018 May 2;66(10):1625-1630. doi: 10.1093/cid/cix992.
4
Genetic variants and their association with phenotypic resistance to bedaquiline in : a systematic review and individual isolate data analysis.遗传变异及其与贝达喹啉对表型耐药性的关联：系统评价和个体分离株数据分析。
Lancet Microbe. 2021 Nov;2(11):e604-e616. doi: 10.1016/s2666-5247(21)00175-0. Epub 2021 Aug 31.
5
Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.临床结核分枝杆菌分离株中贝达喹啉的敏感性降低和耐药性。
J Infect. 2020 May;80(5):527-535. doi: 10.1016/j.jinf.2020.01.007. Epub 2020 Jan 23.
6
Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China.中国陕西流行结核分枝杆菌分离株的分子特征及对贝达喹啉的体外药敏性。
Int J Infect Dis. 2020 Oct;99:163-170. doi: 10.1016/j.ijid.2020.07.044. Epub 2020 Jul 29.
7
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.评估利福平耐药结核病患者对贝达喹啉耐药的流行病学、遗传特征和临床结局：一项横断面和纵向研究。
Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12.
8
Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.国家结核病规划中低收入国家结核病化疗原则。
Indian J Tuberc. 2020 Dec;67(4S):S16-S22. doi: 10.1016/j.ijtb.2020.11.010. Epub 2020 Nov 28.
9
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.中国耐贝达喹啉和德拉马尼的结核分枝杆菌流行率。
J Glob Antimicrob Resist. 2021 Sep;26:241-248. doi: 10.1016/j.jgar.2021.06.007. Epub 2021 Jun 30.
10
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE.鉴定 AtpE 中新型贝达喹啉耐药突变的经验方法。
PLoS One. 2019 May 29;14(5):e0217169. doi: 10.1371/journal.pone.0217169. eCollection 2019.
本文引用的文献
1
India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further.印度应加快获取以贝达喹啉为基础的全口服治疗方案，而不是进一步拖延。
Lung India. 2021 Nov-Dec;38(6):590-591. doi: 10.4103/lungindia.lungindia_425_21.
2
Emergence of bedaquiline resistance in a high tuberculosis burden country.在结核病负担较高的国家出现了贝达喹啉耐药性。
Eur Respir J. 2022 Mar 24;59(3). doi: 10.1183/13993003.00621-2021. Print 2022 Mar.
3
WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?《世界卫生组织2020年结核病综合指南：迈向全口服治疗方案》：各国应匆忙行动吗？
Lung India. 2021 Jul-Aug;38(4):303-306. doi: 10.4103/lungindia.lungindia_982_20.
4
Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment.在俄罗斯，广泛耐药结核分枝杆菌流行株在长期治疗期间频繁获得对贝达喹啉的耐药性。
Clin Microbiol Infect. 2021 Mar;27(3):478-480. doi: 10.1016/j.cmi.2020.08.030. Epub 2020 Sep 3.
5
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients.耐多药结核病合并艾滋病毒感染患者中的贝达喹啉耐药性
Eur Respir J. 2020 Jun 4;55(6). doi: 10.1183/13993003.02383-2019. Print 2020 Jun.
6
Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.耐贝达喹啉结核病：地平线上的乌云。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1564-1568. doi: 10.1164/rccm.201909-1819LE.
7
Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.耐多药结核病的短程治疗方案：十年证据
J Clin Med. 2019 Dec 25;9(1):55. doi: 10.3390/jcm9010055.
8
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.巴基斯坦结核病治疗后获得贝达喹啉和氯法齐明的交叉耐药性。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00915-19. Print 2019 Sep.
9
New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?世界卫生组织关于耐多药结核病的新治疗建议：我们准备得够充分吗？
Am J Respir Crit Care Med. 2019 Aug 15;200(4):514-515. doi: 10.1164/rccm.201902-0260LE.
10
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.一项针对耐利福平结核病的较短疗程的试验。
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
Zotero 插件